scholarly journals The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

2020 ◽  
Author(s):  
Mohammed Eslam ◽  
Shiv K. Sarin ◽  
Vincent Wai-Sun Wong ◽  
Jian-Gao Fan ◽  
Takumi Kawaguchi ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Disease ◽  
Fatty Liver ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Fatty Liver Disease ◽  
Diagnosis And Management ◽  
Asian Pacific

scholarly journals Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020

2021 ◽  
Vol 51 (10) ◽  
pp. 1013-1025
Author(s):  
Katsutoshi Tokushige ◽  
Kenichi Ikejima ◽  
Masafumi Ono ◽  
Yuichiro Eguchi ◽  
Yoshihiro Kamada ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Nonalcoholic Steatohepatitis ◽  
Fatty Liver Disease ◽  
Evidence Based ◽  
Nonalcoholic Fatty Liver

scholarly journals Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

2015 ◽  
Vol 45 (4) ◽  
pp. 363-377 ◽  
Author(s):  
Sumio Watanabe ◽  
Etsuko Hashimoto ◽  
Kenichi Ikejima ◽  
Hirofumi Uto ◽  
Masafumi Ono ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Nonalcoholic Steatohepatitis ◽  
Fatty Liver Disease ◽  
Evidence Based ◽  
Nonalcoholic Fatty Liver

scholarly journals Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020

2021 ◽  
Author(s):  
Katsutoshi Tokushige ◽  
Kenichi Ikejima ◽  
Masafumi Ono ◽  
Yuichiro Eguchi ◽  
Yoshihiro Kamada ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Fibrosis ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Nonalcoholic Steatohepatitis ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Effective Screening

AbstractNonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan.

Comment to: “EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease”

2017 ◽  
Vol 66 (2) ◽  
pp. 465-466 ◽  
Author(s):  
Jorge Fonseca ◽  
Gonçalo Nunes ◽  
Cristina Fonseca ◽  
Manuela Canhoto ◽  
Ana Teresa Barata ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Disease ◽  
Fatty Liver ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document